About: COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs
Creator	Agrawal, Rupesh Seng, De Smet, Marc Gupta, Vishali Kempen, John Lee, Cecilia Nguyen, Quan Pavesio, Carlos Smith, Justine Thng, Zheng Thorne, Jennifer Zierhut, Manfred Mccluskey, Peter Ophthalmology, Tan
source	Medline; PMC
abstract	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan city, Hubei province, China. This is the third and largest coronavirus outbreak since the new millennium after SARS in 2002 and Middle East respiratory syndrome (MERS) in 2012. Over 3 million people have been infected and the COVID-19 has caused more than 217 000 deaths. A concern exists regarding the vulnerability of patients who have been treated with immunosuppressive drugs prior or during this pandemic. Would they be more susceptible to infection by the SARS-CoV-2 and how would their clinical course be altered by their immunosuppressed state? This is a question the wider medical fraternity—including ophthalmologists, rheumatologists, gastroenterologist and transplant physicians among others—must answer. The evidence from the SARS and MERS outbreak offer some degree of confidence that immunosuppression is largely safe in the current COVID-19 pandemic. Preliminary clinical experiences based on case reports, small series and observational studies show the morbidity and mortality rates in immunosuppressed patients may not differ largely from the general population. Overwhelmingly, current best practice guidelines worldwide recommended the continuation of immunosuppression treatment in patients who require them except for perhaps high-dose corticosteroid therapy and in patients with associated risk factors for severe COVID-19 disease.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1136/bjophthalmol-2020-316586
bibo:pmid	32532764
has license	no-cc
sha1sum (hex)	cd062042960df69b1a577e56c2b6440c45aeb01a
schema:url	https://doi.org/10.1136/bjophthalmol-2020-316586
resource representing a document's title	COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs
has PubMed Central identifier	PMC7316101
has PubMed identifier	32532764
schema:publication	Br J Ophthalmol
resource representing a document's body	covid:cd062042960df69b1a577e56c2b6440c45aeb01a#body_text
is schema:about of	named entity 'COVID-19 pandemic' named entity 'COVID' named entity 'SARS' named entity 'immunosuppression' named entity 'rheumatologists' named entity 'acute lung injury' named entity 'immunosuppression' named entity 'immunosuppressed' named entity 'biological therapy' named entity '28 February' named entity 'zoonotic transmission' named entity 'IL-6' named entity 'alkylating agents' named entity 'immunosuppression' named entity 'COVID' named entity 'risk factors' named entity 'comorbidities' named entity 'general population' named entity 'IL-1β' named entity 'epidemiological' named entity 'COVID-19 pandemic' named entity 'SARS' named entity 'corticosteroid' named entity 'corticosteroids' named entity 'COVID-19 disease' named entity 'high levels' named entity 'case reports' named entity 'Corticosteroids' named entity 'COVID-19' named entity 'humanised monoclonal antibody' named entity 'immunosuppression' named entity 'SARS-CoV-2' named entity 'older age' named entity 'lymphopenia' named entity 'MERS' named entity 'MERS' named entity 'SARS-CoV-2' named entity 'immune response' named entity 'risk factors' named entity 'critically ill patients' named entity 'immunosuppression' named entity 'COVID-19 disease' named entity 'endocytosis' named entity 'immunosuppression' named entity 'immune-mediated' named entity 'infection' named entity 'MERS' named entity 'immunosuppressed' named entity 'corticosteroid therapy' named entity 'IBD' named entity 'inflammation' named entity 'Wuhan' named entity 'hypertension' named entity 'kinase' named entity 'mycophenolate mofetil' named entity 'target specific' named entity 'endocytosis' named entity 'IBD' named entity 'biologic therapies' named entity 'prednisone' named entity 'renal transplant' named entity 'spike proteins' named entity 'IL-6' named entity 'oncology' named entity 'long-term' named entity 'coronavirus outbreak' named entity 'IBD' named entity 'Hubei province, China'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software